2021
DOI: 10.1016/j.bpg.2021.101762
|View full text |Cite
|
Sign up to set email alerts
|

Adverse effects of immunosuppression after liver transplantation

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

1
29
0
2

Year Published

2022
2022
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 25 publications
(32 citation statements)
references
References 56 publications
1
29
0
2
Order By: Relevance
“…Dialysis can help slow the progression of chronic kidney disease to a certain extent, but other treatments are limited, leaving kidney transplantation as the only option [ 27 ]. Immunosuppressive medications such as cyclosporine, sirolimus, corticosteroids, and azathioprine are used to prevent organ rejection in patients but can have serious adverse effects such as nephrotoxicity, diabetes, hypertension, increased infection risk, blood clots, seizures, and cardiovascular problems [ 28 ].…”
Section: Conventional Treatments and The Nanotechnology-based Approac...mentioning
confidence: 99%
“…Dialysis can help slow the progression of chronic kidney disease to a certain extent, but other treatments are limited, leaving kidney transplantation as the only option [ 27 ]. Immunosuppressive medications such as cyclosporine, sirolimus, corticosteroids, and azathioprine are used to prevent organ rejection in patients but can have serious adverse effects such as nephrotoxicity, diabetes, hypertension, increased infection risk, blood clots, seizures, and cardiovascular problems [ 28 ].…”
Section: Conventional Treatments and The Nanotechnology-based Approac...mentioning
confidence: 99%
“…A higher percentage of ACR is reported in liver transplant recipients, where 25–60% of children and up to 25% of adults can experience at least one episode of rejection in the first-year post-transplant, while the rate of rejection in kidney transplant has been reported to range from 5 to 20% in recent years [ 9 – 14 ]. Prevention and treatment of rejection requires the lifelong burden of immunosuppression that is inevitably associated with increased risk of infection, de novo malignancy, and cardiovascular and chronic kidney disease and thus directly impacts long-term survival and quality of life [ 15 , 16 ]. On the other hand, a subset of SOT recipients can retain stable allograft function while receiving reduced doses of immunosuppressive drugs or after being completely weaned off immunosuppression, achieving a state of “operational tolerance” [ 17 – 19 ].…”
Section: Introductionmentioning
confidence: 99%
“…Some important side effects reported in the medical literature include nephrotoxicity, hypertension, post‐transplant diabetes mellitus (PTMD), new‐onset diabetes after transplantation (NODAT), dyslipidemia, and modification of the cardiovascular risk profile. 2 Multiple electrolyte disorders, such as hyperkalemia, hypomagnesemia, hypercalciuria, and metabolic acidosis, have also been reported. 3 Cardiovascular adverse effects such as NODAT, dyslipidemia, and arterial hypertension with an increased risk of stroke, myocardial infarction, and heart failure have been described.…”
Section: Introductionmentioning
confidence: 99%